We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+37.6%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$232M
AUM Growth
+$52.7M
Cap. Flow
+$13.9M
Cap. Flow %
6%
Top 10 Hldgs %
61.94%
Holding
59
New
16
Increased
15
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$6.62M
2
WHWK
Whitehawk Therapeutics
WHWK
+$4.21M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.18M
4
BCAB icon
BioAtla
BCAB
+$3.4M
5
UTHR icon
United Therapeutics
UTHR
+$3.24M

Top Sells

Rank Stock Value
1
VTGN icon
VistaGen Therapeutics
VTGN
+$10M
2
RCUS icon
Arcus Biosciences
RCUS
+$4.24M
3
OBIO icon
Orchestra BioMed
OBIO
+$3.91M
4
DTIL icon
Precision BioSciences
DTIL
+$3.28M
5
MRUS
Merus
MRUS
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 90.75%
2 Financials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$37.8M 16.29%
554,000
– –
WHWK
2
Whitehawk Therapeutics
WHWK
$196M
$26.1M 11.25%
1,849,402
+320,000
+21% +$4.21M
BLU
3
DELISTED
BELLUS Health Inc.
BLU
$15.2M 6.54%
1,438,500
+622,500
+76% +$6.62M
RLMD icon
4
Relmada Therapeutics
RLMD
$556M
$13.5M 5.83%
365,618
+13,118
+4% +$363K
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$10.1M 4.35%
563,607
– –
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.02B
$9.84M 4.24%
272,500
– –
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$8.45M 3.64%
843,122
– –
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.7B
$7.8M 3.36%
324,614
+119,611
+58% +$2.68M
CLDX icon
9
Celldex Therapeutics
CLDX
$2.96B
$7.51M 3.23%
267,195
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$7.44M 3.2%
362,735
+128,709
+55% +$2.31M
RLMD icon
11
PUT
Relmada Therapeutics
RLMD
$556M
$7.4M 3.19%
+200,000
New +$5.54M
KURA icon
12
Kura Oncology
KURA
$816M
$7.33M 3.16%
536,500
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.32M 3.15%
104,800
+10,300
+11% +$762K
VTYX
14
DELISTED
Ventyx Biosciences
VTYX
$6.28M 2.71%
180,000
+58,000
+48% +$1.28M
UTHR icon
15
United Therapeutics
UTHR
$25.7B
$5.76M 2.48%
27,500
+14,500
+112% +$3.24M
JYAC
16
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.61M 2.41%
562,500
– –
MIST icon
17
Milestone Pharmaceuticals
MIST
$139M
$5.49M 2.36%
597,026
+139,826
+31% +$1.06M
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.68B
$4.59M 1.98%
+41,500
New +$4.18M
BCAB icon
19
BioAtla
BCAB
$5.41M
$4M 1.72%
+10,400
New +$3.4M
GOSS icon
20
Gossamer Bio
GOSS
$84.9M
$3.41M 1.47%
284,500
+252,500
+789% +$3.13M
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
$3.03M 1.3%
+290,000
New +$3.23M
ARWR icon
22
Arrowhead Research
ARWR
$12.1B
$2.89M 1.25%
87,500
+25,574
+41% +$1.03M
GHRS icon
23
GH Research
GHRS
$1.93B
$2.83M 1.22%
243,250
– –
ACRS icon
24
Aclaris Therapeutics
ACRS
$772M
$2.53M 1.09%
160,835
-32,000
-17% -$504K
EYPT icon
25
EyePoint Inc
EYPT
$1.04B
$2.4M 1.03%
303,396
– –
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Acuta Capital Partners held 59 positions worth $232M, up 29% from $179M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners deployed $13.9M of net new capital in Q3 2022, opening 16 new positions and adding to 15 existing holdings. Its largest new stake was Sarepta Therapeutics: 41,500 shares worth $4.59M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $2.27M trimmed.

  • Acuta Capital Partners's largest Q3 2022 buy was Sarepta Therapeutics: 41,500 shares worth $4.59M.
  • Acuta Capital Partners added most to BELLUS Health Inc. in Q3 2022, an estimated $6.62M increase.
  • Acuta Capital Partners's biggest Q3 2022 reduction was Merus, cutting an estimated $2.27M.
  • Acuta Capital Partners fully exited VistaGen Therapeutics in Q3 2022, selling an estimated $10M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $232M portfolio in Q3 2022.
  • Acuta Capital Partners opened 16 new positions and closed 12 in Q3 2022.
  • Acuta Capital Partners's portfolio value rose 29% quarter-over-quarter to $232M.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.